Dune Medical Devices strives to improve the standard of care for cancer patients every single day. With a first indication in breast cancer, our proprietary radiofrequency spectroscopy platform has been utilized in over 10,000 patients. Our first device, MarginProbe, has been shown to reduce re-excision rates in lumpectomy surgery by 62%.
And we are not stopping there. Our RF platform based biopsy device is currently in development thanks in part to a $3 million EC Horizon 2020 grant.
If you would like to know more about our business and its potential, contact email@example.com.